( ts takingstatins continue to have clin...)Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy,Health

ts taking statins continue to have clinical events, and increasing HDL has been widely accepted as a potential major new approach in reducing the residual risk of a heart attack or stroke in high-risk patients taking statin drugs. The results obtained with the imaging techniques, including IVUS, clearly indicate that imaging trials can be an effective way to obtain and assess data which can be useful in determining the potential of new HDL therapies. Existing epidemiological data and pre-clinical animal studies continue to provide us with overwhelming evidence that higher levels of HDL, or increasing the functionality of existing HDL, will result in reduced cardiovascular disease. Twenty years after the introduction of statins, HDL therapy is clearly now the new frontier. The field is wide open to pursue innovative solutions focused on HDL therapy, and the unmet clinical need is clear."

In a recent study report in the March 26, 2007 issue of The New England Journal of Medicine, Dr. John J.P. Kastelein, Academic Medical Centre, University of Amsterdam, and member of the Lipid Sciences' Scientific Advisory Board noted, that even with the most aggressive treatment, (statin) drugs reduce the risk of a major coronary event by only 30%. This finding, combined with a projection that mortality from cardiovascular causes will increase worldwide by 90% by the year 2020, as compared with that in 1990, illustrates the need for new efficacious treatments for cardiovascular disease.

Furthermore, as an industry expert, Dr. Brewer was recently featured in a Medscape interview, "Raising High-Density Lipoprotein Cholesterol: What Are We Learning From the Torcetrapib Experience?" providing perspective on the current state of HDL Therapy and its future potential. The full text of the article will be available on our website: www.lipidsciences.com at the Lipid Sciences in the News heading.

Lipid Sciences'
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Inspire Announces Presentations at Two European Scientific Conferences
6. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
7. IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
8. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
9. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
10. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
11. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007